Literature DB >> 12390318

Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo.

A Bergamini1, M Cepparulo, F Bolacchi, A Araco, G Tisone, D Ombres, G Rocchi, M Angelico.   

Abstract

Here, CD40L expression and cytokine production have been analysed in peripheral blood cells from orthotopic liver transplantation (OLT) recipients treated with ribavirin for recurrent chronic hepatitis C. The study included 18 OLT recipients treated with ribavirin, eight control OLT recipients and 10 healthy controls. FACS analysis showed that baseline expression of CD40L was not different between ribavirin-treated patients and controls. In contrast, after stimulation with both HCV core antigen and phorbol myristate acetate (PMA) plus ionomycin (IO), the expression of CD40L on CD4 lymphocytes was significantly higher in the ribavirin group compared with controls. In the ribavirin group, the increased expression of CD40L significantly correlated with reduction of HCV RNA levels with respect to pretreatment values. Finally, ribavirin treatment was not associated with modification of PMA-IO-induced cytokine production by T lymphocytes and interleukin (IL)-1beta and tumour necrosis-alpha (TNF)-alpha production by CD40L-stimulated monocytes. In conclusion, these data indicate that ribavirin -upmodulates CD40L expression on CD4 T cells, a property which may account in part for its ability to enhance the antiviral activity of interferon-alpha in the treatment of chronic HCV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390318      PMCID: PMC1906526          DOI: 10.1046/j.1365-2249.2002.01970.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

1.  Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

Authors:  J T Brouwer; B E Hansen; H G Niesters; S W Schalm
Journal:  J Hepatol       Date:  1999-02       Impact factor: 25.083

2.  Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.

Authors:  G Barbaro; G Di Lorenzo; M Soldini; G Giancaspro; G Bellomo; G Belloni; B Grisorio; M Annese; D Bacca; R Francavilla; G Rizzo; G Barbarini
Journal:  Am J Gastroenterol       Date:  1998-12       Impact factor: 10.864

3.  Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

Authors:  R C Tam; B Pai; J Bard; C Lim; D R Averett; U T Phan; T Milovanovic
Journal:  J Hepatol       Date:  1999-03       Impact factor: 25.083

4.  Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response.

Authors:  Q Ning; D Brown; J Parodo; M Cattral; R Gorczynski; E Cole; L Fung; J W Ding; M F Liu; O Rotstein; M J Phillips; G Levy
Journal:  J Immunol       Date:  1998-04-01       Impact factor: 5.422

5.  Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity.

Authors:  H Zylberberg; A C Rimaniol; S Pol; A Masson; D De Groote; P Berthelot; J F Bach; C Bréchot; F Zavala
Journal:  J Hepatol       Date:  1999-02       Impact factor: 25.083

6.  Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients.

Authors:  J Martín; S Navas; J A Quiroga; M Pardo; V Carreño
Journal:  Cytokine       Date:  1998-08       Impact factor: 3.861

7.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

8.  Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus.

Authors:  J H Lee; M von Wagner; W K Roth; G Teuber; C Sarrazin; S Zeuzem
Journal:  J Hepatol       Date:  1998-07       Impact factor: 25.083

9.  The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses.

Authors:  C Hultgren; D R Milich; O Weiland; M Sällberg
Journal:  J Gen Virol       Date:  1998-10       Impact factor: 3.891

10.  Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells.

Authors:  M Rincón; J Anguita; T Nakamura; E Fikrig; R A Flavell
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.